Efficacy and safety of oxybutynin transdermal system in spinal cord injury patients with neurogenic detrusor overactivity and incontinence: an open-label, dose-titration study.

@article{Kennelly2009EfficacyAS,
  title={Efficacy and safety of oxybutynin transdermal system in spinal cord injury patients with neurogenic detrusor overactivity and incontinence: an open-label, dose-titration study.},
  author={Michael J. Kennelly and Gary E. Lemack and Jenelle E Foote and Cynthia S Trop},
  journal={Urology},
  year={2009},
  volume={74 4},
  pages={741-5}
}
OBJECTIVES To evaluate the efficacy and safety of oxybutynin transdermal system (oxybutynin-TDS) in spinal cord injury patients with neurogenic detrusor overactivity and incontinence despite use of clean intermittent catheterization (CIC). METHODS This multicenter, open-label, dose-titration study included patients > or = 18 years old. During an 8-week dose-titration period, oxybutynin-TDS doses were adjusted every 2 weeks, depending on symptoms. The primary efficacy end point was a change in… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 11 extracted citations

Medical management of neurogenic bladder with oral therapy

Translational andrology and urology • 2016
View 14 Excerpts
Highly Influenced

Consultation in Neurourology

Springer International Publishing • 2018
View 2 Excerpts

Neurogenic bladder in spinal cord injury patients

Research and reports in urology • 2015
View 1 Excerpt

Guidelines on neurogenic lower urinary tract dysfunction.

Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie • 2007

Similar Papers

Loading similar papers…